Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218406 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL4840325 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL15430187 | 0.84 | SMN1; SMN2 (0.46) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL30557106 | 0.84 | CTDSP1 (0.54) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL2392771 | 0.83 | KMT2A (0.55) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL2084609 | 0.83 | KMT2A (0.55) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL29755206 | 0.83 | KMT2A (0.55) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL3127858 | 0.82 | CES2 (0.50) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL3127863 | 0.82 | CES2 (0.50) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL15041050 | 0.82 | KMT2A (0.60) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096304-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3957/4885MEN1 4292/4885KMT2A 3803/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3957/4885MEN1 4292/4885KMT2A 3803/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3957/4885MEN1 4292/4885KMT2A 3803/4885 |
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ALDH1A1 2261/4885MEN1 1959/4885KMT2A 3308/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3957/4885MEN1 4292/4885KMT2A 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.